We provide you with 20 years of free, institutional-grade data for TIL stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of TIL. Explore the full financial landscape of TIL stock.
| Reported Date | CIK | Ticker | Type |
|---|
Instil Bio, Inc.(NASDAQ:TIL) 
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, ...
Website: http://instilbio.com
Founded: 2018
CEO: Bronson Crouch
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about TIL stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.